Apr 17 |
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
|
Apr 9 |
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
|
Apr 8 |
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
|
Apr 8 |
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
|
Mar 20 |
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
|
Mar 8 |
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
|
Mar 5 |
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
|
Mar 5 |
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
Mar 1 |
Celldex prices $400.4M stock offering
|
Mar 1 |
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
|